Trial Profile
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2020
Price :
$35
*
At a glance
- Drugs Azilsartan medoxomil (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Acronyms CONSORT-compliant
- Sponsors Takeda
- 07 Aug 2020 Primary endpoint (Change from baseline to week 8 in trough Sitting Clinic Systolic Blood Pressure (SBP): AZL-M 40-mg group to 160-mg valsartan group), has been met according to results published in the Medicine
- 07 Aug 2020 Primary endpoint (Change from baseline to week 8 in trough Sitting Clinic Systolic Blood Pressure (SBP): AZL-M 80-mg group to valsartan 160-mg group), has been met according to results published in the Medicine
- 07 Aug 2020 Results published in the Medicine